Europe on Thursday passed a non-binding resolution calling on Germany to compensate all European victims of the drug thalidomide, which caused deformities in thousands of children in the late 1950s and early 1960s.
The members of the European Parliament formally requested Berlin to compensate not only German victims -- which the German government is set to do in 2017 following an amendment to the so-called "Thalidomide law" -- but also pay European victims, reports Efe.
The resolution approved in a plenary session also called on the Spanish government to review its 2010 legislation and to provide a new registry of those affected by the immunomodulatory drug so they can exercise their right to compensation.
However, the resolution is not a law and does not require Germany to take the action suggested.
German pharmaceutical Grünenthal first marketed the drug in 1957, in West Germany, under the trade name Contergan.
It was often prescribed as a sedative or hypnotic and primarily used against nausea and morning sickness in pregnant women.
The drug was later sold in over 50 countries across the world under more than 80 different trade names.
In 1961, it was discovered that thalidomide caused severe malformations to those subjected to the drug in the womb such that thousands of children were born without limbs or with underdeveloped arms and legs that were mere stumps.
--IANS
vgu/dg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
